<code id='993FAC7161'></code><style id='993FAC7161'></style>
    • <acronym id='993FAC7161'></acronym>
      <center id='993FAC7161'><center id='993FAC7161'><tfoot id='993FAC7161'></tfoot></center><abbr id='993FAC7161'><dir id='993FAC7161'><tfoot id='993FAC7161'></tfoot><noframes id='993FAC7161'>

    • <optgroup id='993FAC7161'><strike id='993FAC7161'><sup id='993FAC7161'></sup></strike><code id='993FAC7161'></code></optgroup>
        1. <b id='993FAC7161'><label id='993FAC7161'><select id='993FAC7161'><dt id='993FAC7161'><span id='993FAC7161'></span></dt></select></label></b><u id='993FAC7161'></u>
          <i id='993FAC7161'><strike id='993FAC7161'><tt id='993FAC7161'><pre id='993FAC7161'></pre></tt></strike></i>

          Home / fashion / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:259
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In